Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: pacritinib, pacritinib citrate | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 1,630 | 0.73 |
| pathways Reactome | 18 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 11920
Sealed predictions
- IRAK1 in dopamine neurons, braak+0.37 (p 0.329) → -0.60 (p 0.089)receipt 11927
Swarm cases
receipt 11927: IRAK1 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.715, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.538, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.609, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to +0.03, sign flips 1; without severely affected donors -0.09 (p 0.715, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IRAK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts